Orally Administered Fentanyl Products

Trade name	Generic	Administration	Available strengths	Bioavailability	Cmax	*Tmax
	name				(ng/mL)	(minutes)
Actiq	Fentanyl	Lozenge that is placed	200 mcg	Rapid ~25% from	400 mcg – 0.63	20-120
	citrate	btwn the lower gum and	400 mcg	the mucosa,		
		cheek and left in place	600 mcg	remaining	800 mcg – 1.03	
		for 15 minutes	800 mcg	swallowed with		
			1200 mcg	saliva and slowly		
			1600 mcg	absorbed from GI		
				tract – total 47 %		
Fentora	Fentanyl	Tablet for buccal	100 mcg	Rapid ~50%	100 mcg – 0.25	35-46.8
	citrate	administration – place in	200 mcg	absorbed from the	200 mcg – 0.40	
		the buccal cavity above	300 mcg	mucosa, remaining	400 mcg – 1.02	
		the rear molar, takes 14-	400 mcg	swallowed with	800 mcg – 1.59	
		25 minutes to dissolve,	600 mcg	saliva and slowly		
		any remnants can be	800 mcg	absorbed from GI		
		swallowed with water		tract – total 65%		
Onsolis	Fentanyl	2 layer film placed on the	200 mcg	Rapid 51%	800 mcg – 1.67	60-150
	citrate	inside of the cheek,	400 mcg	absorbed from the		
		dissolves in 15-30	600 mcg	mucosa, remaining		
		minutes	800 mcg	swallowed with		
			1200 mcg	saliva and slowly		
				absorbed from GI		
				tract – total 71 %		
Abstral	Fentanyl	Sublingual tablet placed	100 mcg	Rapid absorption	100 mcg -0.187	30-60
	citrate	under the tongue	200 mcg	occurs over about	200 mcg – 0.302	
			300 mcg	30 minutes. Total	400 mcg – 0.765	
			400 mcg	54%	800 mcg – 1.42	
			600 mcg			
			800 mcg			

^{*}dose dependent, mucositis does not appear to affect peak plasma concentrations

These products must not be used in opioid non-tolerant patients due to the risk of life-threatening hypoventilation. They are not approved for the treatment of acute pain (e.g., post-operative, dental, migraine). In addition, switching between these fentanyl products must not occur at a 1:1 ratio due to differences in drug delivery and absorption profiles. Two of these products (Abstral and Onsolis) require REMS monitoring by the FDA and prescriber enrollment.